AUTHOR=El Massioui Nicole , Lamirault Charlotte , Yagüe Sara , Adjeroud Najia , Garces Daniel , Maillard Alexis , Tallot Lucille , Yu-Taeger Libo , Riess Olaf , Allain Philippe , Nguyen Huu Phuc , von Hörsten Stephan , Doyère Valérie TITLE=Impaired Decision Making and Loss of Inhibitory-Control in a Rat Model of Huntington Disease JOURNAL=Frontiers in Behavioral Neuroscience VOLUME=10 YEAR=2016 URL=https://www.frontiersin.org/journals/behavioral-neuroscience/articles/10.3389/fnbeh.2016.00204 DOI=10.3389/fnbeh.2016.00204 ISSN=1662-5153 ABSTRACT=

Cognitive deficits associated with Huntington disease (HD) are generally dominated by executive function disorders often associated with disinhibition and impulsivity/compulsivity. Few studies have directly examined symptoms and consequences of behavioral disinhibition in HD and its relation with decision-making. To assess the different forms of impulsivity in a transgenic model of HD (tgHD rats), two tasks assessing cognitive/choice impulsivity were used: risky decision-making with a rat gambling task (RGT) and intertemporal choices with a delay discounting task (DD). To assess waiting or action impulsivity the differential reinforcement of low rate of responding task (DRL) was used. In parallel, the volume as well as cellular activity of the amygdala was analyzed. In contrast to WT rats, 15 months old tgHD rats exhibited a poor efficiency in the RGT task with difficulties to choose advantageous options, a steep DD curve as delays increased in the DD task and a high rate of premature and bursts responses in the DRL task. tgHD rats also demonstrated a concomitant and correlated presence of both action and cognitive/choice impulsivity in contrast to wild type (WT) animals. Moreover, a reduced volume associated with an increased basal cellular activity of the central nucleus of amygdala indicated a dysfunctional amygdala in tgHD rats, which could underlie inhibitory dyscontrol. In conclusion, tgHD rats are a good model for impulsivity disorder that could be used more widely to identify potential pharmacotherapies to treat these invasive symptoms in HD.